Term ends May 18, 2029 · Medium confidence
20-year base term ends Mar 12, 2028
Why Medium: A parent in the chain could not be resolved.
Held by Nektar Therapeutics
Filed Sep 11, 2009 as application 12/558,395 · Granted May 8, 2012
Base term plus 432 days of patent term adjustment (USPTO delay)
Today
2008
2029
Clock starts
Mar 12, 2008
Mar 12, 2008
Term ends
May 18, 2029
May 18, 2029
Granted
May 8, 2012
May 8, 2012
base term
patent term adjustment
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
432
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
21
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 432 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 12, 2008, when application PCT/US2008/003353, the earliest non-provisional in its chain, was filed (this one was filed Sep 11, 2009); a parent in its chain could not be resolved (the next row) | Mar 12, 2028 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +432 days, USPTO patent term adjustment record | May 18, 2029 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 18, 2029 | Medium confidence |
This family
| Application PCT/US2008/003353 | PCT application no patent term | no patent term |
| US 8,173,666 | this patent May 2029 | May 2029 |
| Application PCT/US2009/005174 | PCT application no patent term | no patent term |
| Application PCT/US2010/042792 | PCT application no patent term | no patent term |
| Application 13/063,919 | Abandoned not computed | not computed |
| US 8,440,687 | In force Mar 2028 | Mar 2028 |
| US 8,575,196 | In force Mar 2028 | Mar 2028 |
| US 8,569,343 | In force Mar 2028 | Mar 2028 |
8 of 21 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 6, 2009 Reel 23484, frame 664 | Riggs-sauthier, Jennifer; Deng, Bo-liang; Riley, Timothy A. | Nektar Therapeutics | Assignment of Assignor's Interest |
| Jul 17, 2012 Reel 28571, frame 141 | Nektar Therapeutics | Wells Fargo Bank, National Association, as Collateral Agent | Grant of Security Interest |
| Oct 6, 2015 Reel 36796, frame 562 | Nektar Therapeutics | TC Lending, LLC, as Collateral Agent | Grant of Security Interest in United States Patents |
| Oct 14, 2015 Reel 36866, frame 700 | Wells Fargo Bank, National Association, as Collateral Agent | Nektar Therapeutics | Release of Security Interest Recorded at Reel 28571, Frame 0141 |
| Oct 28, 2019 Reel 50846, frame 940 | Inheris Pharmaceuticals, Inc. | TC Lending, LLC, as Collateral Agent | Security Interest |
| Oct 28, 2019 Reel 50846, frame 461 | Nektar Therapeutics | Inheris Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 15, 2019 Reel 51038, frame 585 | Inheris Pharmaceuticals, Inc. | Inheris Biopharma, Inc. | Change of Name |
| Apr 17, 2020 Reel 52435, frame 62 | TC Lending, LLC, as Collateral Agent | Inheris Biopharma, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 53180, frame 9 | TC Lending, LLC, as Collateral Agent | Nektar Therapeutics | Release of Security Interest |
| Jan 9, 2023 Reel 62313, frame 501 | Inheris Biopharma, Inc. | Nektar Therapeutics | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2029
Term ends May 18, 2029. No further fees fall due before then
Note
The 432 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
52
later US patents cite this one
That is top 25% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.